Clinical Trials Logo
  1. Home
  2. Neoplasm, Breast
  3. NCT05392608

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) — SEQUEL-Breast  

Neoplasm, Breast Clinical Trial

Official title:
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast): A Phase 2 Study on Fulvestrant Beyond Progression in Combination With Alpelisib for PIK3CA-mutated, Hormone-receptor Positive HER2 Negative Advanced Breast Cancer

Clinical Trial Summary

The study is a nationwide, multicenter single-arm phase 2 study. The current phase 2 study investigates the efficacy of the combination of fulvestrant and alpelisib directly after progression on fulvestrant (either in first or second line, with or without previous use of CDK4/6-inhibitor) in patients with HR+ HER2- advanced breast cancer with PIK3CA mutated tumors. All eligible patients must have progressive disease on fulvestrant as latest treatment line. Previous treatment with a CDK4/6 inhibitor in first or second line is obligatory. After progressive disease is confirmed, it is important to continue fulvestrant (without CDK4/6 inhibition) during the screening period awaiting study enrollment. After study enrollment all participants will be treated with alpelisib and fulvestrant beyond progression. Follow-up time will be until progression or death or until a different oncolytic treatment has started (in case no progressive disease during previous fulvestrant and alpelisib treatment has been documented). Should participants discontinue due to reasons other than progression or death (e.g. toxicity), then they should still be evaluated for disease progression every 8 weeks as per protocol until progression, unless they do not wish to proceed with these screenings, or receive a different oncolytic treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05392608
Study type Interventional
Source Borstkanker Onderzoek Groep
Contact Annemarie C.A.M. Almekinders, MD
Phone 020 512 2439
Email sequel@nki.nl
Status Recruiting
Phase Phase 2
Start date June 2, 2022
Completion date March 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05851053 - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting NCT05507034 - Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.
Recruiting NCT03715686 - To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes N/A
Recruiting NCT06337214 - TCM Therapy Program Impact on Breast Cancer Patients' Vital Energy N/A
Recruiting NCT05033769 - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer Phase 4
Recruiting NCT05512260 - Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs N/A
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2
Recruiting NCT04109079 - Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy N/A
Not yet recruiting NCT05465031 - Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) Phase 4
Completed NCT04678544 - Cooling Cap Trial to Prevent Permanent Chemotherapy-induced Alopecia in Breast Cancer Patients N/A
Recruiting NCT03756064 - Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer N/A
Completed NCT03368196 - DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein Phase 1